You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
As part of the placement, the Singapore-based firm has issued almost 17.9 million new ordinary shares at an issue price of $.175 per share.
The firm will use the funding to expand access to its microbial cell-free DNA technology to help doctors diagnose infectious disease.
The company plans to use the funds to fuel its diagnostic development work, focused on predicting drug response in various autoimmune diseases.
The company said the funding will support international expansion of its FebriDx rapid point-of-care test and its US clinical trial.
The Stockholm-based company said it will use the funds to develop its metabolism-based liquid biopsy platform.
The financing round comes as Color expands its partnerships with healthcare systems and builds out a national genetic counseling resource for NIH's All of Us program.
Of the 39 deals included in the analysis, only three exceeded $100 million in value, with the rest having significantly smaller price tags or prices that were not disclosed.
To market its analyte specific reagents, syndromic enteric panels, and other tests, the firm is building a US-based sales organization.
The funding will be used to bring to market Oklahoma City-based Progentec's products for CLIA labs, as well as its digital technologies for managing lupus.
While it continues to seek investments, the firm is also making preparations for an initial public offering on the Nasdaq First North exchange.